
Image: Arcutis Biotherapeutics, maker of Zoryve. Shown to identify the product. KindleeRx is not affiliated with Arcutis Biotherapeutics.
Can You Stop Zoryve When Your Skin Clears?

Chief Medical Officer
Yes, you can stop Zoryve when your skin clears, but expect the rash to come back, and for eczema I prefer stepping down to twice a week over stopping cold. The label gives no stop rule and no time limit (Zoryve cream label). In a 52-week psoriasis study, adults who stopped at clear skin restarted after a median of 8.0 weeks in one group and 12.4 weeks in the other (ClinicalTrials.gov NCT03764475).
In this article
Can you stop Zoryve once your skin is clear?
Yes; nothing in the label stops you, and nothing in the label tells you to stop. The dosing section says to apply once daily, with no maximum length, no area limit and no instruction to stop when clear (Zoryve cream label).
The main trials never tested stopping. Patients kept applying the cream to every area marked at the start, even after it cleared (Lebwohl 2022). Stopping was studied only in open-label studies, where everyone knew they were on Zoryve.
Here is what I tell patients. With psoriasis or seborrheic dermatitis, stop when clear and restart at the first sign of return. With eczema, drop to twice a week on the spots that tend to flare. Whether eczema can go away for good is its own question, covered in can eczema be cured permanently.
Does the rash come back after you stop Zoryve?
Usually, yes, after a few weeks to a few months. In the 52-week psoriasis study, 29 adults reached "clear" and stopped on all spots; they restarted after a median of 8.0 weeks (n = 23) and 12.4 weeks (n = 6) (ClinicalTrials.gov NCT03764475).
Seborrheic dermatitis stayed away longer. In a 52-week foam study, patients stopped when completely clear and called before restarting; the 34.5% who cleared and stopped went a median of 22.7 weeks without treatment (Alexis 2026). Both studies were open label, and the psoriasis group was only 29 people. To find what sets off your flares, read understanding eczema triggers.
Is there rebound or withdrawal when you stop Zoryve?
No Zoryve study I reviewed reports a rebound, and Zoryve is not a steroid. The label classifies roflumilast as a phosphodiesterase-4 (PDE4) inhibitor, and the eczema trial report calls it nonsteroidal (Zoryve cream label; Simpson 2024). I could not find a study that stopped Zoryve and measured a flare worse than the starting point. When the usual rash comes back after stopping, I treat it as the underlying disease returning and restart.
Zoryve also kept working with steady use. Over 52 weeks of once-daily cream 0.3% in 332 adults with psoriasis, no tachyphylaxis (fading effect) was seen (Stein Gold 2024).
Can you use Zoryve twice a week for maintenance?
Yes, in studies; the label itself lists only once-daily use. In the eczema extension for ages 6 and up, patients who became fully clear on cream 0.15% switched to twice-weekly "proactive" use on normal-looking, flare-prone skin, and stayed clear or almost clear for a median of 281 days (Simpson 2026).
Children aged 2 to 5 did the same with cream 0.05% on 2 nonconsecutive days a week. Of the 170 children (30.2%) who switched, disease control lasted a median of 238 days, about 8 months (Eichenfield 2026). Neither study compared twice weekly against stopping. For eczema, I suggest two nonconsecutive days, such as Monday and Thursday, on the old flare sites, and daily use again if a patch returns.
How long can you stay on Zoryve?
The label sets no time limit, and safety data run up to 64 weeks. The label reports that safety over up to 64 weeks in 644 psoriasis patients matched the short trials, and an eczema extension enrolled 1,219 patients (Zoryve cream label). In children, 104 used the 0.15% cream and 353 used the 0.05% cream for 52 weeks (same label).
In the 52-week adult psoriasis study, 3.9% stopped for side effects, 3.6% had treatment-related side effects (none serious), at least 97% had no irritation, and about 45% were clear or almost clear at week 52 (Stein Gold 2024). Patients who kept using the cream daily after clearing stayed clear or almost clear for a median of 189 days (ClinicalTrials.gov NCT04286607).
Does the same plan apply to compounded roflumilast?
The plan can, the data cannot. Every relapse time and maintenance result above comes from branded Zoryve at the strengths tested. Compounded drugs are not approved by the Food and Drug Administration (FDA), and the FDA does not verify their safety, effectiveness or quality before they are sold (FDA 2025). With any roflumilast cream, I use the same logic: once daily until clear, then the lowest use that keeps you clear, decided with the clinician who prescribes it.
How does KindleeRx treat eczema and psoriasis?
The KindleeRx Calming Cream is a compounded prescription cream with roflumilast 0.2% and calamine 5%, used once daily for mild to moderate eczema or psoriasis when a clinician decides it is appropriate. Licensed clinicians (physician assistants and nurse practitioners working under a board-certified dermatologist's protocols) review each case online and reply in under 5 hours on average. A prescription is never guaranteed, and if treatment is not prescribed, the refund is full, including the consultation fee. Our eczema guide covers daily skin care between flares.
Important Information
The KindleeRx Calming Cream is a compounded prescription medication containing roflumilast 0.2% and calamine 5%, prepared by a licensed US compounding pharmacy under a licensed prescriber. It is not Zoryve, it is not a generic of Zoryve, and it is not an FDA-approved drug product. Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality. KindleeRx is not affiliated with Arcutis or Zoryve. Published trial data for branded roflumilast (Zoryve) reflect the branded product and the branded concentrations studied in those trials, not this compounded formula. Eligibility is determined by a licensed clinician after reviewing your information. Not all patients qualify. This article is educational and is not medical advice.
Sources
- Arcutis Biotherapeutics. ZORYVE (roflumilast) cream prescribing information and Patient Information, revised June 2026. DailyMed.
- ClinicalTrials.gov. NCT03764475, 52-week open-label study of roflumilast cream 0.3% in psoriasis, posted results.
- ClinicalTrials.gov. NCT04286607, DERMIS-OLE posted results.
- Stein Gold L, et al. Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis. Journal of the American Academy of Dermatology 2024.
- Lebwohl MG, et al. DERMIS-1 and DERMIS-2 trials of roflumilast cream 0.3% in plaque psoriasis. JAMA 2022.
- Simpson EL, et al. INTEGUMENT-1 and INTEGUMENT-2 trials of roflumilast cream 0.15% in atopic dermatitis. JAMA Dermatology 2024.
- Simpson EL, et al. Long-term safety and efficacy of roflumilast cream 0.15% in patients aged 6 and older with atopic dermatitis. Dermatitis 2026.
- Eichenfield LF, et al. INTEGUMENT-OLE extension in children aged 2 to 5. Pediatric Dermatology 2026.
- Alexis AF, et al. 52-week open-label study of roflumilast foam 0.3% in seborrheic dermatitis. American Journal of Clinical Dermatology 2026.
- US Food and Drug Administration. Compounding and the FDA: Questions and Answers. 2025.



